3,3'-diindolylmethane has been researched along with Cancer of Prostate in 40 studies
3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist
| Excerpt | Relevance | Reference |
|---|---|---|
| "In conclusion, ring-DIMs inhibited prostate cancer cell growth and induced cell death in LNCaP and PC-3 cells with greater potencies than DIM; they also structure-dependently activated different cell death pathways suggesting that these compounds have clinical potential as chemopreventive and chemotherapeutic agents in prostate cancer, regardless of hormone-dependency." | 5.40 | Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells. ( Abdelbaqi, K; Beach, A; Goldberg, AA; Safe, S; Sanderson, JT; Titorenko, VI, 2014) |
| "DIM induces apoptosis in prostate cancer cells via the mitochondria- and death receptor-mediated pathways." | 5.37 | 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. ( Cho, HJ; Kim, EJ; Kim, JK; Park, JH; Park, SY, 2011) |
| "The administration of BR-DIM to prostate cancer patients before prostatectomy yields detectable plasma levels but without consistent or significant tissue accumulation or biomarker modulation." | 2.82 | Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. ( Bailey, HH; Gee, JR; Harris, L; Havighurst, TC; House, M; Huang, W; Jarrard, D; Kim, K; Kolesar, J; Messing, E; Parnes, H; Saltzstein, DR; Wollmer, BW, 2016) |
| "NGD16 suppressed the viability of prostate cancer (PC-3), pancreatic adenocarcinoma (MiaPaca-2), colorectal cancer (COLO-205) and human umbilical vein endothelial cells (HUVECs) effectively with IC50 values 0." | 1.42 | A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78). ( Amin, H; Goswami, A; Gupta, AP; Kushwaha, M; Mukherjee, D; Nayak, D; Rah, B; Sharma, D; Ur Rasool, R, 2015) |
| "In conclusion, ring-DIMs inhibited prostate cancer cell growth and induced cell death in LNCaP and PC-3 cells with greater potencies than DIM; they also structure-dependently activated different cell death pathways suggesting that these compounds have clinical potential as chemopreventive and chemotherapeutic agents in prostate cancer, regardless of hormone-dependency." | 1.40 | Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells. ( Abdelbaqi, K; Beach, A; Goldberg, AA; Safe, S; Sanderson, JT; Titorenko, VI, 2014) |
| "In the present studies, we utilized prostate cancer cell culture models to elucidate the mechanisms of action of broccoli-derived phytochemicals 3,3'-diindolylmethane (DIM) and indole-3-carbinol (I3C)." | 1.38 | Broccoli-derived phytochemicals indole-3-carbinol and 3,3'-diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: comparison with other cancer preventive phytochemicals. ( Kim, YS; Milner, JA; Schoene, NW; Wang, TT, 2012) |
| " We previously reported that a formulated DIM (BR-DIM; hereafter referred as B-DIM) with higher bioavailability was able to induce apoptosis and inhibit cell growth, angiogenesis, and invasion of prostate cancer cells." | 1.38 | Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo. ( Banerjee, S; Chen, D; Cui, QC; Dou, QP; Kong, D; Sarkar, FH, 2012) |
| "DIM induces apoptosis in prostate cancer cells via the mitochondria- and death receptor-mediated pathways." | 1.37 | 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. ( Cho, HJ; Kim, EJ; Kim, JK; Park, JH; Park, SY, 2011) |
| "Cruciferous vegetables protect against prostate cancer." | 1.37 | Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells. ( Abdelbaqi, K; Guns, ET; Kotha, L; Lack, N; Safe, S; Sanderson, JT, 2011) |
| "Mouse prostate cancer cells (TRAMP-C2, 2x10) were injected subcutaneously into three groups of C57BL/6 mice (10 mice in each group)." | 1.36 | The potential efficacy of 3,3'-diindolylmethane in prevention of prostate cancer development. ( Appel, B; Azzam, N; Fares, B; Fares, F; Stein, A, 2010) |
| "Human prostate cancer cells of the line PC-3M were cultured and then divided into the following groups: control group with solvent added into the culture fluid; IDA groups, with IDA of the terminal concentrations of 0." | 1.35 | [3,3-diindolylmethane enhances the inhibitory effect of idarubicin on the growth of human prostate cancer cells]. ( Li, Y; Liu, YN; Pan, YZ; Yu, H; Zhao, LJ; Zhao, XJ; Zhao, YY; Zhou, L, 2008) |
| " This study examined the potential of these phytochemicals to reduce the adverse effects of E2 on PCa." | 1.35 | 3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. ( Auborn, KJ; Bradlow, HL; Sepkovic, D; Smith, S, 2008) |
| " We found that BioResponse DIM (B-DIM), a formulated DIM with higher bioavailability, inhibited angiogenesis and invasion by reducing the bioavailability of vascular endothelial growth factor (VEGF) via repressing extracellular matrix-degrading proteases, such as matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), in human prostate cancer cells and reduced vascularity (angiogenesis) in vivo using Matrigel plug assay." | 1.34 | Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. ( Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z, 2007) |
| "Since all men die with prostate cancer rather than of the disease, it is of particular interest to prevent or delay the progression of the disease by chemopreventive strategies." | 1.33 | 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. ( Ashok, BT; Garikapaty, VP; Mittelman, A; Tadi, K; Tiwari, RK, 2006) |
| "Prostate cancer is the most common malignancy and the second leading cause of male death in Western countries." | 1.32 | Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway. ( Fares, FA; Nachshon-Kedmi, M; Yannai, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (47.50) | 29.6817 |
| 2010's | 20 (50.00) | 24.3611 |
| 2020's | 1 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Tsao, CW | 1 |
| Li, JS | 1 |
| Lin, YW | 1 |
| Wu, ST | 1 |
| Cha, TL | 1 |
| Liu, CY | 1 |
| Palomera-Sanchez, Z | 2 |
| Watson, GW | 1 |
| Wong, CP | 2 |
| Beaver, LM | 3 |
| Williams, DE | 3 |
| Dashwood, RH | 3 |
| Ho, E | 3 |
| Draz, H | 1 |
| Goldberg, AA | 2 |
| Titorenko, VI | 2 |
| Tomlinson Guns, ES | 1 |
| Safe, SH | 1 |
| Sanderson, JT | 3 |
| Yu, J | 1 |
| Feng, Y | 1 |
| Wang, Y | 1 |
| An, R | 1 |
| Kim, EK | 1 |
| Kim, YS | 2 |
| Milner, JA | 2 |
| Wang, TT | 2 |
| Wu, TY | 1 |
| Khor, TO | 1 |
| Su, ZY | 1 |
| Saw, CL | 1 |
| Shu, L | 1 |
| Cheung, KL | 1 |
| Huang, Y | 1 |
| Yu, S | 1 |
| Kong, AN | 1 |
| Beach, A | 1 |
| Abdelbaqi, K | 2 |
| Safe, S | 2 |
| Hsu, A | 1 |
| Buchanan, A | 1 |
| Houseman, EA | 1 |
| Kiselev, VI | 1 |
| Drukh, VM | 1 |
| Muyzhnek, EL | 1 |
| Kuznetsov, IN | 1 |
| Pchelintseva, OI | 1 |
| Paltsev, MA | 1 |
| Nayak, D | 1 |
| Amin, H | 1 |
| Rah, B | 1 |
| Ur Rasool, R | 1 |
| Sharma, D | 1 |
| Gupta, AP | 1 |
| Kushwaha, M | 1 |
| Mukherjee, D | 1 |
| Goswami, A | 1 |
| Gee, JR | 1 |
| Saltzstein, DR | 1 |
| Messing, E | 1 |
| Kim, K | 1 |
| Kolesar, J | 1 |
| Huang, W | 2 |
| Havighurst, TC | 1 |
| Harris, L | 1 |
| Wollmer, BW | 1 |
| Jarrard, D | 1 |
| House, M | 1 |
| Parnes, H | 1 |
| Bailey, HH | 1 |
| Zhao, YY | 1 |
| Zhou, L | 1 |
| Pan, YZ | 1 |
| Zhao, LJ | 1 |
| Liu, YN | 1 |
| Yu, H | 1 |
| Li, Y | 8 |
| Zhao, XJ | 1 |
| Smith, S | 1 |
| Sepkovic, D | 1 |
| Bradlow, HL | 1 |
| Auborn, KJ | 2 |
| Chinnakannu, K | 1 |
| Chen, D | 2 |
| Wang, Z | 7 |
| Dou, QP | 3 |
| Reddy, GP | 2 |
| Sarkar, FH | 10 |
| Ahmad, A | 3 |
| Kong, D | 7 |
| Sarkar, SH | 1 |
| Banerjee, S | 7 |
| Vivar, OI | 1 |
| Lin, CL | 1 |
| Firestone, GL | 3 |
| Bjeldanes, LF | 3 |
| Rahman, KM | 1 |
| Ali, S | 2 |
| Sakr, WA | 1 |
| Khwaja, FS | 1 |
| Wynne, S | 1 |
| Posey, I | 1 |
| Djakiew, D | 1 |
| Fares, F | 1 |
| Azzam, N | 1 |
| Appel, B | 1 |
| Fares, B | 1 |
| Stein, A | 1 |
| Cho, HJ | 1 |
| Park, SY | 1 |
| Kim, EJ | 1 |
| Kim, JK | 1 |
| Park, JH | 1 |
| Lack, N | 1 |
| Guns, ET | 1 |
| Kotha, L | 1 |
| Schoene, NW | 1 |
| Singh-Gupta, V | 1 |
| Yunker, CK | 1 |
| Rakowski, JT | 1 |
| Joiner, MC | 1 |
| Konski, AA | 1 |
| Hillman, GG | 1 |
| Bao, B | 1 |
| Yu, TW | 1 |
| Sokolowski, EI | 1 |
| Tsai, JY | 1 |
| Chou, CT | 1 |
| Liu, SI | 1 |
| Liang, WZ | 1 |
| Kuo, CC | 1 |
| Liao, WC | 1 |
| Lin, KL | 1 |
| Hsu, SS | 1 |
| Lu, YC | 1 |
| Huang, JK | 1 |
| Jan, CR | 1 |
| Cui, QC | 1 |
| Groome, NM | 1 |
| Elboray, EE | 1 |
| Inman, MW | 1 |
| Dondas, HA | 1 |
| Phillips, RM | 1 |
| Kilner, C | 1 |
| Grigg, R | 1 |
| Le, HT | 1 |
| Schaldach, CM | 1 |
| Li, X | 1 |
| Nachshon-Kedmi, M | 3 |
| Yannai, S | 3 |
| Haj, A | 1 |
| Fares, FA | 3 |
| Hsu, JC | 1 |
| Zhang, J | 1 |
| Dev, A | 1 |
| Wing, A | 1 |
| Garikapaty, VP | 1 |
| Ashok, BT | 1 |
| Tadi, K | 1 |
| Mittelman, A | 1 |
| Tiwari, RK | 1 |
| Savino, JA | 1 |
| Evans, JF | 1 |
| Rabinowitz, D | 1 |
| Carter, TH | 1 |
| Bhuiyan, MM | 1 |
| Ahmed, F | 1 |
| Murthy, S | 1 |
| Sheng, S | 1 |
| Kim, HR | 1 |
1 trial available for 3,3'-diindolylmethane and Cancer of Prostate
| Article | Year |
|---|---|
Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Biomarkers, Tumor; Double-Blind Method; Follow-Up Studies; | 2016 |
39 other studies available for 3,3'-diindolylmethane and Cancer of Prostate
| Article | Year |
|---|---|
Regulation of carcinogenesis and mediation through Wnt/β-catenin signaling by 3,3'-diindolylmethane in an enzalutamide-resistant prostate cancer cell line.
Topics: Benzamides; Carcinogenesis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indoles; Male; Nitr | 2021 |
The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatin; Chrom | 2017 |
Diindolylmethane and its halogenated derivatives induce protective autophagy in human prostate cancer cells via induction of the oncogenic protein AEG-1 and activation of AMP-activated protein kinase (AMPK).
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Carcinogenesis; Cell Adhesion Molecules; Cell L | 2017 |
Aryl hydrocarbon receptor enhances the expression of miR-150-5p to suppress in prostate cancer progression by regulating MAP3K12.
Topics: Cell Proliferation; Disease Progression; Down-Regulation; Gene Knockdown Techniques; Humans; Indoles | 2018 |
Indole-3-carbinol and 3',3'-diindolylmethane modulate androgen's effect on C-C chemokine ligand 2 and monocyte attraction to prostate cancer cells.
Topics: Androgens; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Cell Adhesion; Cell Movement; Cell | 2013 |
Epigenetic modifications of Nrf2 by 3,3'-diindolylmethane in vitro in TRAMP C1 cell line and in vivo TRAMP prostate tumors.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Epigenesis, Genetic; Female; Indoles; Male; Mice | 2013 |
Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells.
Topics: Androgens; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Dihydrotestosteron | 2014 |
Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells.
Topics: Analysis of Variance; Anticarcinogenic Agents; Cells, Cultured; Chromatin Immunoprecipitation; DNA M | 2014 |
Preclinical antitumor activity of the diindolylmethane formulation in xenograft mouse model of prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship | 2014 |
A therapeutically relevant, 3,3'-diindolylmethane derivative NGD16 attenuates angiogenesis by targeting glucose regulated protein, 78kDa (GRP78).
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug | 2015 |
[3,3-diindolylmethane enhances the inhibitory effect of idarubicin on the growth of human prostate cancer cells].
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Prolif | 2008 |
3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.
Topics: Anticarcinogenic Agents; Base Sequence; Catechol O-Methyltransferase; Cell Line, Tumor; Cell Prolife | 2008 |
Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells.
Topics: Apoptosis; Cell Cycle; Cell Line; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Humans; | 2009 |
Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration.
Topics: Anticarcinogenic Agents; Apoptosis; Cell Movement; Cell Proliferation; Gene Silencing; Humans; Indol | 2009 |
3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status.
Topics: Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhi | 2009 |
3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Lin | 2009 |
3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.
Topics: 3T3 Cells; Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents | 2009 |
The potential efficacy of 3,3'-diindolylmethane in prevention of prostate cancer development.
Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Indoles; Male; Mice; Mice, Inbred C57BL; Phospha | 2010 |
3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Ap | 2011 |
Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Line, Tumor; Humans; Indoles; Male; Prostate-Speci | 2011 |
Broccoli-derived phytochemicals indole-3-carbinol and 3,3'-diindolylmethane exerts concentration-dependent pleiotropic effects on prostate cancer cells: comparison with other cancer preventive phytochemicals.
Topics: Androgens; Anticarcinogenic Agents; Biomarkers, Tumor; Brassica; Cell Proliferation; Cyclin-Dependen | 2012 |
B-DIM impairs radiation-induced survival pathways independently of androgen receptor expression and augments radiation efficacy in prostate cancer.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell P | 2012 |
Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis.
Topics: Bone Neoplasms; Bone Remodeling; Cadherins; Cell Differentiation; Cell Line, Tumor; Coculture Techni | 2012 |
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.
Topics: Androgens; Anticarcinogenic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase In | 2012 |
Effect of diindolylmethane on Ca2+ homeostasis and viability in PC3 human prostate cancer cells.
Topics: Calcium; Calcium Signaling; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; Fura-2; Homeosta | 2012 |
Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Enzyme Activation; Humans; Indoles; Male; | 2012 |
Carbophilic 3-component cascades: access to complex bioactive cyclopropyl diindolylmethanes.
Topics: Antineoplastic Agents; Catalysis; Cell Line; Cyclopropanes; Humans; Indoles; Male; Palladium; Prosta | 2013 |
Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Animals; Anticarcinogenic Agents; Binding, Competiti | 2003 |
Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis.
Topics: Cell Division; DNA, Complementary; Gene Expression Profiling; Gene Expression Regulation, Neoplastic | 2003 |
Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells.
Topics: Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Division; Cell Survival; Dose-R | 2003 |
Therapeutic activity of 3,3'-diindolylmethane on prostate cancer in an in vivo model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cell Survival; Indoles; Male; Mice; Mice, | 2004 |
Induction of apoptosis in human prostate cancer cell line, PC3, by 3,3'-diindolylmethane through the mitochondrial pathway.
Topics: Androgens; Anticarcinogenic Agents; Apoptosis; Cytochromes c; Cytosol; Diet; Humans; Indoles; Male; | 2004 |
Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
Topics: Anticarcinogenic Agents; Cell Proliferation; Chloramphenicol; Down-Regulation; Flow Cytometry; G1 Ph | 2005 |
3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer.
Topics: Androgens; Anticarcinogenic Agents; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cel | 2006 |
Multiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane.
Topics: Apoptosis; Benzylamines; Calcium; Calcium Signaling; Chelating Agents; Cyclosporine; Cytosol; Egtazi | 2006 |
Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
Topics: Androgen Receptor Antagonists; Anticarcinogenic Agents; Apoptosis; Bone Neoplasms; Cell Growth Proce | 2006 |
Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Topics: Anticarcinogenic Agents; Cell Line, Tumor; DNA, Neoplasm; Down-Regulation; Endothelial Cells; Humans | 2007 |
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Anticarcinogenic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; | 2007 |
Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in platelet-derived growth factor-D-overexpressing PC3 cells.
Topics: Cell Growth Processes; Cell Line, Tumor; Enzyme Activation; Humans; Indoles; Lymphokines; Male; Neop | 2008 |